EP2526933B1
(en)
|
2006-09-22 |
2015-02-25 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
ES2403546T3
(es)
*
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
SG10201508035TA
(en)
*
|
2007-03-28 |
2015-10-29 |
Pharmacyclics Inc |
Inhibitors of bruton's tyrosine kinase
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
AU2008314632B2
(en)
|
2007-10-19 |
2015-05-28 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US20100101977A1
(en)
*
|
2008-06-05 |
2010-04-29 |
United Comb & Novelty Corporation |
Stackable Packaging For Lipped Containers
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP3549934A1
(en)
|
2008-06-27 |
2019-10-09 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
JP5369183B2
(ja)
|
2008-07-16 |
2013-12-18 |
ファーマサイクリックス,インク. |
固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Egfr 억제제 및 질환 치료방법
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
CA3154024C
(en)
|
2010-06-03 |
2024-02-27 |
Pharmacyclics Llc |
Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
|
BR112013003388A2
(pt)
|
2010-08-10 |
2016-07-12 |
Celgene Avilomics Res Inc |
sal de besilato de um inibidor de btk
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
JP5957460B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
複素環式化合物またはその使用
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
EP2710005B1
(en)
|
2011-05-17 |
2016-10-05 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
JP2014520863A
(ja)
|
2011-07-13 |
2014-08-25 |
ファーマサイクリックス,インク. |
Bruton型チロシンキナーゼの阻害剤
|
WO2013013188A1
(en)
|
2011-07-21 |
2013-01-24 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
CN104284584B
(zh)
|
2012-03-15 |
2019-06-04 |
西建卡尔有限责任公司 |
表皮生长因子受体激酶抑制剂的盐
|
WO2013138495A1
(en)
|
2012-03-15 |
2013-09-19 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
US9296753B2
(en)
|
2012-06-04 |
2016-03-29 |
Pharmacyclics Llc |
Crystalline forms of a Bruton's tyrosine kinase inhibitor
|
MX2015001081A
(es)
|
2012-07-24 |
2015-10-14 |
Pharmacyclics Inc |
Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
|
CN103121999A
(zh)
*
|
2012-08-29 |
2013-05-29 |
苏州迪飞医药科技有限公司 |
一种酪氨酸激酶抑制剂pci-32765的合成方法
|
PT2892900T
(pt)
|
2012-09-10 |
2017-11-06 |
Principia Biopharma Inc |
Compostos de pirazolopirimidina como inibidores de cinase
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CN104854107A
(zh)
|
2012-11-15 |
2015-08-19 |
药品循环公司 |
作为激酶抑制剂的吡咯并嘧啶化合物
|
CN103864797A
(zh)
*
|
2012-12-10 |
2014-06-18 |
韩冰 |
一类具有神经保护作用的化合物及其用途
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US9145387B2
(en)
|
2013-02-08 |
2015-09-29 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
WO2014151871A2
(en)
|
2013-03-14 |
2014-09-25 |
Tolero Pharmaceuticals, Inc. |
Jak2 and alk2 inhibitors and methods for their use
|
KR102377688B1
(ko)
|
2013-03-15 |
2022-03-22 |
얀센 파마슈티카 엔.브이. |
약제를 제조하기 위한 방법 및 중간체
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
EP2989106B1
(en)
|
2013-04-25 |
2016-12-14 |
Beigene, Ltd. |
Fused heterocyclic compounds as protein kinase inhibitors
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
EP3027192A4
(en)
|
2013-08-02 |
2017-03-22 |
Pharmacyclics, LLC |
Methods for the treatment of solid tumors
|
JP6035423B2
(ja)
|
2013-08-12 |
2016-11-30 |
大鵬薬品工業株式会社 |
新規な縮合ピリミジン化合物又はその塩
|
CA2920534A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmacyclics Llc |
Methods for the treatment of her2 amplified cancer
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
ES2792183T3
(es)
|
2013-09-13 |
2020-11-10 |
Beigene Switzerland Gmbh |
Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
|
SG11201602421VA
(en)
|
2013-09-30 |
2016-04-28 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
KR102452866B1
(ko)
|
2013-10-25 |
2022-10-07 |
파마싸이클릭스 엘엘씨 |
이식편 대 숙주 질환의 치료 및 예방 방법
|
CA2833701A1
(en)
*
|
2013-11-19 |
2015-05-19 |
Pharmascience Inc. |
Protein kinase inhibitors
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
CN104945404B
(zh)
*
|
2014-06-25 |
2018-09-14 |
广东东阳光药业有限公司 |
一种n-丙烯羰基哌啶衍生物的制备方法
|
CN110156892B
(zh)
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
WO2016022942A1
(en)
|
2014-08-07 |
2016-02-11 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
CN104447761A
(zh)
*
|
2014-11-27 |
2015-03-25 |
广东东阳光药业有限公司 |
一种吡唑衍生物的制备方法
|
CN104478884A
(zh)
*
|
2014-12-05 |
2015-04-01 |
广东东阳光药业有限公司 |
一种中间体的制备方法
|
CN107209186A
(zh)
*
|
2014-12-11 |
2017-09-26 |
默克专利有限公司 |
Btk抑制剂的测定
|
WO2016100593A1
(en)
*
|
2014-12-17 |
2016-06-23 |
Pharmacyclics Llc |
Methods and assays for quantification and normalization of kinase and ligand binding
|
CN107257686B
(zh)
|
2014-12-18 |
2021-01-29 |
普林斯匹亚生物制药公司 |
天疱疮的治疗
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
KR20220029783A
(ko)
|
2015-01-20 |
2022-03-08 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
JP6093485B2
(ja)
*
|
2015-01-30 |
2017-03-08 |
大鵬薬品工業株式会社 |
免疫疾患の予防及び/又は治療剤
|
SG11201707122QA
(en)
|
2015-03-03 |
2017-09-28 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
|
MX2017011919A
(es)
|
2015-03-18 |
2018-05-22 |
Arvinas Inc |
Compuestos y metodos para la degradacion mejorada de proteinas especificas.
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
JP7337502B2
(ja)
|
2015-09-16 |
2023-09-04 |
ロクソ オンコロジー, インコーポレイテッド |
がんの治療のためのbtk阻害剤としてのピラゾロピリミジン誘導体
|
UA127863C2
(uk)
|
2015-12-16 |
2024-01-31 |
Локсо Онколоджі, Інк. |
Сполуки, які можна застосовувати як інгібітори кінази
|
US20200216454A1
(en)
*
|
2015-12-30 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for her3 degradation and methods of use
|
US11034991B2
(en)
|
2016-03-16 |
2021-06-15 |
Oryzon Genomics S.A. |
Methods to determine KDM1A target engagement and chemoprobes useful therefor
|
SG11201811255WA
(en)
|
2016-06-29 |
2019-01-30 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
CN109563099B
(zh)
|
2016-08-16 |
2023-02-03 |
百济神州有限公司 |
一种化合物的晶型、其制备和用途
|
WO2018033135A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
CA3087528C
(en)
|
2016-09-15 |
2024-01-30 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
KR20190058550A
(ko)
|
2016-09-19 |
2019-05-29 |
메이 파마, 아이엔씨. |
병용 요법
|
CN110506039A
(zh)
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
IL304982A
(en)
|
2016-11-01 |
2023-10-01 |
Arvinas Operations Inc |
PROTACS Targeted Tau-Protein and Related Methods of Use
|
EP3548483A4
(en)
|
2016-12-01 |
2020-06-10 |
Arvinas Operations, Inc. |
TETRAHYDRONAPHTHALINE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS AN ESTROGEN RECEPTOR-DEGRADING AGENT
|
KR102564201B1
(ko)
|
2016-12-23 |
2023-08-07 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
AU2017382406A1
(en)
|
2016-12-23 |
2019-04-18 |
Arvinas Operations, Inc. |
EGFR proteolysis targeting chimeric molecules and associated methods of use
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
TWI774726B
(zh)
|
2017-01-25 |
2022-08-21 |
英屬開曼群島商百濟神州有限公司 |
(S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
|
JP7266526B6
(ja)
|
2017-01-26 |
2024-02-15 |
アルビナス・オペレーションズ・インコーポレイテッド |
エストロゲン受容体タンパク質分解性の調節因子およびその関連方法
|
CN110799543A
(zh)
|
2017-06-26 |
2020-02-14 |
百济神州有限公司 |
肝细胞癌的免疫治疗
|
US11377449B2
(en)
|
2017-08-12 |
2022-07-05 |
Beigene, Ltd. |
BTK inhibitors with improved dual selectivity
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
AU2019249231B2
(en)
|
2018-04-04 |
2022-04-21 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
AU2019247498A1
(en)
|
2018-04-05 |
2020-11-26 |
Sumitomo Pharma Oncology, Inc. |
AXL kinase inhibitors and use of the same
|
JP2021521170A
(ja)
|
2018-04-13 |
2021-08-26 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
CN112912376A
(zh)
|
2018-08-20 |
2021-06-04 |
阿尔维纳斯运营股份有限公司 |
用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
|
MX2021009371A
(es)
|
2019-02-12 |
2021-09-10 |
Sumitomo Pharma Oncology Inc |
Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
KR20220119094A
(ko)
|
2019-12-19 |
2022-08-26 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
TW202235075A
(zh)
*
|
2020-12-17 |
2022-09-16 |
美商艾伯維有限公司 |
雙環吡唑布魯頓氏酪胺酸激酶抑制劑
|
EP4323352A1
(en)
|
2021-04-16 |
2024-02-21 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|
WO2024097653A1
(en)
|
2022-10-31 |
2024-05-10 |
Sumitomo Pharma America, Inc. |
Pim1 inhibitor for treating myeloproliferative neoplasms
|